A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.
Inclusion Criteria:
Exclusion Criteria:
Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).
Jacksonville, Florida 32256, United States
New York, New York 10029, United States
Liptovský Mikuláš, 03123, Slovakia
Durbanville, 7550, South Africa
Dnipro, 49005, Ukraine
Kharkiv, 61091, Ukraine
Kyiv, 01030, Ukraine
Stepanovka, 73488, Ukraine
Ternopil, 46027, Ukraine
Vinnytsia, 21005, Ukraine